Yes, hydromorphone is available in immediate-release formulations.
Hydromorphone comes in immediate-release (IR) oral tablets and solution, as well as parenteral formulations 1. The most recent NCCN guidelines (2025) explicitly state that hydromorphone is available in "oral tablets, solution, and parenteral formulations," with specific mention of hydromorphone IR being used 4-times-daily for cancer pain management 1.
Available Formulations
Immediate-Release Options
- Oral tablets (various strengths)
- Oral solution/liquid
- Parenteral formulations (IV, subcutaneous)
The FDA drug label confirms that hydromorphone immediate-release tablets are rapidly absorbed, with peak plasma concentrations typically attained within ½ to 1 hour after oral administration 2.
Extended-Release Options
Hydromorphone also comes in extended-release (ER) formulations for once-daily dosing, which should be reserved for patients already on stable opioid regimens 1, 3.
Clinical Use of IR Hydromorphone
The immediate-release formulation is specifically used for:
- Dose titration in opioid-naive patients
- Breakthrough pain (4-times-daily dosing)
- Rapid pain control when needed
The NCCN guidelines document that RCTs demonstrated clinical noninferiority of 4-times-daily hydromorphone IR compared with 4-times-daily oxycodone IR for relieving moderate to severe cancer pain 1.
Pharmacokinetic Profile
The immediate-release formulation has:
- Rapid absorption from the GI tract
- Peak effect at 30-60 minutes
- Terminal half-life of approximately 2.3-2.6 hours 2
- Bioavailability of approximately 24% due to extensive first-pass metabolism 2
Important Clinical Considerations
Hydromorphone IR should be distinguished from extended-release formulations when prescribing. The CDC guidelines emphasize that clinicians should initiate opioid treatment with immediate-release opioids instead of ER/LA formulations 3. ER/LA opioids (including extended-release hydromorphone) should be reserved for severe, continuous pain in patients already receiving certain dosages of immediate-release opioids daily.
Research confirms that immediate-release hydromorphone has been extensively studied and used for both acute and chronic cancer pain, with well-established pharmacokinetics and pharmacodynamics 4, 5.